Women are the majority of every published weight-loss trial of these drugs. STEP 4 randomized 803 adults of whom 634, or 79%, were women, at a mean age of 46[1]. SURMOUNT-4 randomized 670 adults of whom 473, or 71%, were women, at a mean age of 48 [2]. Those mean ages sit squarely in the years when the menopausal transition happens, and neither trial reported menopausal status as a prespecified subgroup.
What was searched, and when
The searches behind this page were run against PubMed in September 2026, pairing semaglutide and tirzepatide with menopause, perimenopause, postmenopausal status, vasomotor symptoms and menopausal hormone therapy. No randomized controlled trial reporting outcomes by menopausal status was returned. What came back was a review of pharmacologic options written for a menopause readership [3], a case report [4], and a pharmacokinetic review about progestogens [5]. That is a statement about a search on a date, not a claim that no such work exists anywhere.
The rule this page follows is the one the editorial methodology applies everywhere: an outcome may be stated only where a cited paper measured it. Where nothing measured it, the page says so.
What can honestly be carried across
A trial whose population is 79% women at a mean age of 46 has produced a result that applies to a population including many women in the transition, even though it did not analyze them separately. The weight outcomes in the withdrawal studies were measured in those same populations. What cannot be carried across is anything specific to the transition — whether the response differs before and after the final period, whether the body-composition changes differ, whether vasomotor symptoms interact with the drug at all. None of that was measured.
The hormone therapy question, which is real and unstudied
Many women in this age group take oral progestogens, either for a gynecologic indication or for endometrial protection alongside estrogen. Tirzepatide delays gastric emptying, so an interaction with an oral hormone is biologically plausible. The only pharmacokinetic study available used a combined oral contraceptive rather than a menopausal regimen: a single 5 mg dose of tirzepatide reduced peak concentrations by 55 to 66% and total exposure by 20 to 23% [5].
No equivalent data exists for the progestogens used in menopausal hormone therapy, and the review reporting the contraceptive figures says plainly that findings from one formulation cannot be extrapolated to structurally different agents. The contraception page sets out the same study in more detail. Anyone taking both should treat this as a question for a prescriber rather than a settled matter in either direction.
A single case report, labeled as one
A 2025 case report in Menopause describes worsening vasomotor symptoms in a woman taking estradiol who started semaglutide [4]. One case establishes that the combination was documented once. It does not establish a rate, a mechanism or a direction, and it should not be read as any of those.
What this means when choosing a service
The practical consequence of an unstudied question is that the person prescribing has to be reachable. A service that folds the clinician visit into the monthly price is a different proposition here from one that bills each contact separately or never says how often a patient is reviewed. Those differences are recorded per seller: the visit-inclusive services state it on the pricing page, and the rest are set out across the seller reviews.